Dianthus Therapeutics is a publicly traded, clinical-stage biotechnology company focused on developing innovative monoclonal antibodies with enhanced selectivity and potency. Headquartered in New York City and Waltham, Massachusetts, the company is led by a team of seasoned biotech and pharmaceutical executives dedicated to advancing next-generation antibody complement therapeutics. Dianthus aims to provide transformative treatments for individuals suffering from severe autoimmune and inflammatory diseases, with a commitment to improving patient care and outcomes.